176 related articles for article (PubMed ID: 18571285)
1. Prolyl oligopeptidase stimulates the aggregation of alpha-synuclein.
Brandt I; Gérard M; Sergeant K; Devreese B; Baekelandt V; Augustyns K; Scharpé S; Engelborghs Y; Lambeir AM
Peptides; 2008 Sep; 29(9):1472-8. PubMed ID: 18571285
[TBL] [Abstract][Full Text] [Related]
2. Suggested functions for prolyl oligopeptidase: a puzzling paradox.
Brandt I; Scharpé S; Lambeir AM
Clin Chim Acta; 2007 Feb; 377(1-2):50-61. PubMed ID: 17034776
[TBL] [Abstract][Full Text] [Related]
3. Interactions between metals and alpha-synuclein--function or artefact?
Brown DR
FEBS J; 2007 Aug; 274(15):3766-74. PubMed ID: 17617226
[TBL] [Abstract][Full Text] [Related]
4. Interaction of prolyl oligopeptidase with α-synuclein.
Lambeir AM
CNS Neurol Disord Drug Targets; 2011 May; 10(3):349-54. PubMed ID: 21222624
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of prolyl oligopeptidase increases the survival of alpha-synuclein overexpressing cells after rotenone exposure by reducing alpha-synuclein oligomers.
Dokleja L; Hannula MJ; Myöhänen TT
Neurosci Lett; 2014 Nov; 583():37-42. PubMed ID: 25240592
[TBL] [Abstract][Full Text] [Related]
6. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.
Uversky VN
J Neurochem; 2007 Oct; 103(1):17-37. PubMed ID: 17623039
[TBL] [Abstract][Full Text] [Related]
7. Calpain-resistant fragment(s) of alpha-synuclein regulates the synuclein-cleaving activity of 20S proteasome.
Kim HJ; Lee D; Lee CH; Chung KC; Kim J; Paik SR
Arch Biochem Biophys; 2006 Nov; 455(1):40-7. PubMed ID: 17005155
[TBL] [Abstract][Full Text] [Related]
8. Role of different regions of alpha-synuclein in the assembly of fibrils.
Qin Z; Hu D; Han S; Hong DP; Fink AL
Biochemistry; 2007 Nov; 46(46):13322-30. PubMed ID: 17963364
[TBL] [Abstract][Full Text] [Related]
9. Protein array analysis of oligomerization-induced changes in alpha-synuclein protein-protein interactions points to an interference with Cdc42 effector proteins.
Schnack C; Danzer KM; Hengerer B; Gillardon F
Neuroscience; 2008 Jul; 154(4):1450-7. PubMed ID: 18541383
[TBL] [Abstract][Full Text] [Related]
10. Controlling the mass action of alpha-synuclein in Parkinson's disease.
Kim C; Lee SJ
J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
[TBL] [Abstract][Full Text] [Related]
11. Studies of the aggregation of an amyloidogenic alpha-synuclein peptide fragment.
Madine J; Doig AJ; Kitmitto A; Middleton DA
Biochem Soc Trans; 2005 Nov; 33(Pt 5):1113-5. PubMed ID: 16246058
[TBL] [Abstract][Full Text] [Related]
12. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies.
Fodero-Tavoletti MT; Mulligan RS; Okamura N; Furumoto S; Rowe CC; Kudo Y; Masters CL; Cappai R; Yanai K; Villemagne VL
Eur J Pharmacol; 2009 Sep; 617(1-3):54-8. PubMed ID: 19576880
[TBL] [Abstract][Full Text] [Related]
13. Functional protein kinase arrays reveal inhibition of p-21-activated kinase 4 by alpha-synuclein oligomers.
Danzer KM; Schnack C; Sutcliffe A; Hengerer B; Gillardon F
J Neurochem; 2007 Dec; 103(6):2401-7. PubMed ID: 17883396
[TBL] [Abstract][Full Text] [Related]
14. Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation.
Shaikh S; Nicholson LF
J Neurosci Res; 2008 Jul; 86(9):2071-82. PubMed ID: 18335520
[TBL] [Abstract][Full Text] [Related]
15. A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.
Myöhänen TT; Hannula MJ; Van Elzen R; Gerard M; Van Der Veken P; García-Horsman JA; Baekelandt V; Männistö PT; Lambeir AM
Br J Pharmacol; 2012 Jun; 166(3):1097-113. PubMed ID: 22233220
[TBL] [Abstract][Full Text] [Related]
16. Cleavage of normal and pathological forms of alpha-synuclein by neurosin in vitro.
Kasai T; Tokuda T; Yamaguchi N; Watanabe Y; Kametani F; Nakagawa M; Mizuno T
Neurosci Lett; 2008 May; 436(1):52-6. PubMed ID: 18358605
[TBL] [Abstract][Full Text] [Related]
17. Prolyl oligopeptidase inhibition attenuates the toxicity of a proteasomal inhibitor, lactacystin, in the alpha-synuclein overexpressing cell culture.
Myöhänen TT; Norrbacka S; Savolainen MH
Neurosci Lett; 2017 Jan; 636():83-89. PubMed ID: 27818354
[TBL] [Abstract][Full Text] [Related]
18. Characterization of fibrillation process of alpha-synuclein at the initial stage.
Tashiro M; Kojima M; Kihara H; Kasai K; Kamiyoshihara T; Uéda K; Shimotakahara S
Biochem Biophys Res Commun; 2008 May; 369(3):910-4. PubMed ID: 18329380
[TBL] [Abstract][Full Text] [Related]
19. The aggregation of alpha-synuclein is stimulated by FK506 binding proteins as shown by fluorescence correlation spectroscopy.
Gerard M; Debyser Z; Desender L; Kahle PJ; Baert J; Baekelandt V; Engelborghs Y
FASEB J; 2006 Mar; 20(3):524-6. PubMed ID: 16410343
[TBL] [Abstract][Full Text] [Related]
20. beta-Sheet-breaking peptides inhibit the fibrillation of human alpha-synuclein.
Kim YS; Lim D; Kim JY; Kang SJ; Kim YH; Im H
Biochem Biophys Res Commun; 2009 Oct; 387(4):682-7. PubMed ID: 19622344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
